Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M

seekingalpha02-01

Women's health company Evofem Biosciences (OTCQB:EVFM) Thursday said it achieved preliminary net product sales in the range of $18.1 to $18.3M in 2023. The company added that it improved loss from ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2408633616?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1460419757/image_1460419757.jpg","is_english":true,"pubTime":"2024-02-01 21:48","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2408633616","market":"us","top_or_hot":-1,"title":"Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M","media":"seekingalpha","content":"<div>\n<p>Women's health company Evofem Biosciences (OTCQB:EVFM) Thursday said it achieved preliminary net product sales in the range of $18.1 to $18.3M in 2023. The company added that it improved loss from ...</p>\n\n<a href=\"https://seekingalpha.com/news/4061254-evofem-biosciences-achieves-2023-prelim-net-product-sales-of-181m-to-183m\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-01 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4061254-evofem-biosciences-achieves-2023-prelim-net-product-sales-of-181m-to-183m><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Women's health company Evofem Biosciences (OTCQB:EVFM) Thursday said it achieved preliminary net product sales in the range of $18.1 to $18.3M in 2023. The company added that it improved loss from ...</p>\n\n<a href=\"https://seekingalpha.com/news/4061254-evofem-biosciences-achieves-2023-prelim-net-product-sales-of-181m-to-183m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/4061254-evofem-biosciences-achieves-2023-prelim-net-product-sales-of-181m-to-183m","article_id":"2408633616","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1460419757/image_1460419757.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2408633616","pubTimestamp":1706795324,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Women's health company Evofem Biosciences  Thursday said it achieved preliminary net product sales in the range of $18.1 to $18.3M in 2023. The company added that it improved loss from operations by more than 75% versus 2022 levels. \"Strong consumer demand for Phexxi and the expansion of coverage and reimbursement enabled us to achieve our third consecutive year of revenue growth,\" said Saundra Pelletier, CEO of Evofem Biosciences.  Evofem expects to report full results for the three- and twelve-month periods ended December 31, 2023, in mid-March 2024. Source: Press Release    More on Evofem Biosciences  Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Evofem Biosciences Historical earnings data for Evofem Biosciences Financial information for Evofem Biosciences","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4584":"避孕概念","EVFM":"Evofem Biosciences, Inc."},"translate_title":"Evofem Biosciences实现2023年初步净产品销售额1810万美元至1830万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVFM":1},"content_text":"Women's health company Evofem Biosciences (OTCQB:EVFM) Thursday said it achieved preliminary net product sales in the range of $18.1 to $18.3M in 2023. The company added that it improved loss from operations by more than 75% versus 2022 levels. \"Strong consumer demand for Phexxi and the expansion of coverage and reimbursement enabled us to achieve our third consecutive year of revenue growth,\" said Saundra Pelletier, CEO of Evofem Biosciences.  Evofem expects to report full results for the three- and twelve-month periods ended December 31, 2023, in mid-March 2024. Source: Press Release    More on Evofem Biosciences  Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Evofem Biosciences Historical earnings data for Evofem Biosciences Financial information for Evofem Biosciences","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2408633616"}